Trials / Completed
CompletedNCT01659970
PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 152 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line platinum-based chemotherapy. Eligible patients will be followed for 12 months.
Conditions
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2012-08-08
- Last updated
- 2016-11-02
Locations
110 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01659970. Inclusion in this directory is not an endorsement.